myome®

Proactive Health
INTEGRATED PRS™
BREAST CANCER

Personalized Risk Assessment for Breast Cancer

MyOme's Integrated Polygenic Risk Score™ (iPRS™) Breast Cancer test combines whole-genome insights with clinical risk assessment, delivering a more accurate risk prediction to guide healthcare decisions.



Better Risk Prediction can Tailor Management to Improve Health Outcomes

Beyond Single-Gene Detection

20%

of breast cancers have an underlying genetic risk that cannot be detected by single-gene analysis (e.g., *BRCA1* and *BRCA2* tests)

Broad Eligible Population

Up to **95%**

of individuals do not have a single-gene breast cancer condition but may have genetic risk factors detectable by the iPRS test.[1]

Reliable Risk Stratification

Up to **6%**

of those classified as low-risk by clinical models alone were reclassified as high-risk by iPRS.[2]

iPRS for Breast Cancer

Patients can receive an iPRS result if they:

- Were assigned female at birth and are aged 18-84
- Do not have a personal history of breast cancer
- Do not have a pathogenic variant in a breast cancer-related gene

PRS

Includes >1M genetic risk factors

+

Tyrer-Cuzick Assessment

Includes clinical inputs from health history

 I 535 Middlefield Rd, Suite 170, Menlo Park, CA 94025 I www.myome.com I M-068_C v1 02/25

Proactive Health
INTEGRATED PRS™
BREAST CANCER

Key Features

Multi-Ancestry Applicability

Data from >250K patients in five large international cohorts was used to validate iPRS, enabling cross-ancestry risk prediction[2]

Actionable Recommendations

Results may provide general recommendations for surveillance and treatment or suggest follow-up with a healthcare provider

Genetic Counseling

Optional support from a trained genetic counselor is available to help ensure comprehensive risk assessment and management

Important Considerations: The iPRS Breast Cancer test is intended as a screening tool and does not diagnose a person with breast cancer. Some people with a high risk score will not develop breast cancer and some with a low risk score will develop breast cancer.

A Simple, Seamless Process

Ordering	Sample Collection	Sample Analysis	Receiving Results
Submit a request via MyOme's secure portal	Use instructions provided in blood, saliva, or buccal swab collection kits	Return sample to MyOme for sequencing and data analysis	Reports with risk assessment results and relevant actionable insights are delivered through a secure portal

Support at Every Step

We are committed to helping providers communicate complex topics by providing videos, materials, and other resources to enhance the patient experience.

Get started with MyOme today.
Contact support@myome.com to set up an account.

This test was developed, and its performance characteristics were determined, by MyOme, Inc., a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and College of American Pathologist (CAP) accredited to perform high complexity clinical laboratory testing. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Test results should always be interpreted by a clinician in the context of clinical and familial data with the availability of genetic counseling when appropriate. MyOme is not responsible for the content or accuracy of third-party websites.

1. Garber J.E., Offit K. Hereditary Cancer Predisposition Syndromes. J. Clin. Oncol. 2005;23:276–292. doi: 10.1200/JCO.2005.10.042 **2.** Tshiaba et al., Integration of a Cross-Ancestry Polygenic Model With Clinical Risk Factors Improves Breast Cancer Risk Stratification. JCO Precis Oncol. 2023 Feb;7:e2200447. doi: 10.1200/PO.22.00447.

